Compare Tango Therapeutics Inc. (TNGX) vs Texas Instruments Incorporated (TXN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tango Therapeutics Inc. vs Texas Instruments Incorporated — how do they compare? Tango Therapeutics Inc. trades at $22.5 (market cap $3.74B), while Texas Instruments Incorporated trades at $278.75 (market cap $256.30B). The key difference: Texas Instruments Incorporated is far larger — about 68.5× Tango Therapeutics Inc.'s market cap, and Texas Instruments Incorporated pays a 2.17% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Tango Therapeutics Inc. for 0 Days and Texas Instruments Incorporated for 77 Days on average.
| TNGX | TXN | |
|---|---|---|
Market Cap | $3.74B | $256.30B |
Volume | 3,438,781 | 6,924,604 |
Sector | Health | Technology |
52-Week High | $32.90 | $332.35 |
52-Week Low | $7.50 | $153.33 |
Typical Hold Time | 0 Days | 77 Days |
Enterprise Value | $2.76B | $263.35B |
Dividend Yield | — | 2.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Texas Instruments (TXN) trades at $287.85, up 2.17% with strong technical support at $278 and resistance at $288. The company shows improving fundamentals with Q2 2026 EPS beating expectations at $2.14 versus $1.94, and revenue growth accelerating from $17.7B in 2025 to projected $19.5B in 2026. Operating cash flow strengthened to $7.15B in 2025, supporting consistent dividend payments.
TXN presents a compelling investment case with 47.7% analyst buy ratings and $325 consensus price target offering 13% upside. Key risks include premium valuation (P/E 43.75) and rising debt-to-asset ratio (40.61% in 2025). The data center segment's doubling sales and AI-driven semiconductor demand provide growth catalysts, though competitive pressures and cyclical industry dynamics warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →About Texas Instruments Incorporated
Dallas-based Texas Instruments generates over 95% of its revenue from semiconductors and the remainder from its well-known calculators. Texas Instruments is the world's largest maker of analog chips, which are used to process real-world signals such as sound and power. Texas Instruments also has a leading market share position in processors and microcontrollers used in a wide variety of electronics applications.
Read more on TXN →
